Search - tctmd.com

Displaying 61 - 80 of 108

Sort: Relevancy | Date

News Daily News

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Michael O'Riordan

January 14, 2020

News Daily News

Higher Chili Pepper Consumption Linked to Fewer CVD Deaths

L.A. McKeown

December 17, 2019

News Daily News

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

Michael O'Riordan

December 03, 2019

News Conference News AHA 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

Todd Neale

November 18, 2019

News Daily News

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Michael O'Riordan

August 26, 2019

News Conference News EAS 2019

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

Michael O'Riordan

June 07, 2019

News Conference News SCAI 2019

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

Yael L. Maxwell

June 03, 2019

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for April 2019

Shelley Wood

May 01, 2019

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Daily News

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

Michael O'Riordan

November 07, 2018

News Industry News

AUM Cardiovascular Receives FDA Approval For Revolutionary Diagnostic Heart Device

August 08, 2017

News Daily News

ABSORB II Substudy Digs Into Long-term Arterial Remodeling Following BRS, DES Implantation

Yael L. Maxwell

June 29, 2017

News Daily News

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Michael O'Riordan

January 18, 2017

News Opinion Editor's Corner

Las Noticias y Blogs Más Populares de TCTMD en 2016

Shelley Wood

December 29, 2016

News Daily News

Los Antecedentes de Aterosclerosis Aumentan el Riesgo de Morir Post-IAM

Michael O'Riordan

December 09, 2016

News Daily News

USPSTF: Counseling on Diet and Exercise Helpful but Not Mandatory for CVD Prevention

Caitlin E. Cox

December 02, 2016

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

September 20, 2016

News Daily News

Más con Menos: Un Análisis de Rentabilidad Dice que Hay que Reducir en Dos Tercios el Precio de PCSK9

Yael L. Maxwell

August 29, 2016

News Conference News ESC 2016

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

Michael O'Riordan

August 27, 2016

Advertisement

Lp(a) Reduction Contributes to Alirocumab’s Treatment Benefit: ODYSSEY Outcomes

Higher Chili Pepper Consumption Linked to Fewer CVD Deaths

Non-HDL Cholesterol Strongly Tied to Lifetime CVD Risk

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

Highest Risk, Biggest Benefit in ACS Patients Treated With Alirocumab: ODYSSEY OUTCOMES

Should Lp(a) Be Measured and Treated? Two Experts Hash Out Its Current Role

LDL Apheresis Potentially a ‘Head Start’ to Conventional Lipid-Lowering Methods Post-PCI in ACS: PREMIER

CHD Mortality Significantly Elevated in Patients With Severe FH

TCTMD’s Top 10 Most Popular Stories for April 2019

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

ODYSSEY Outcomes Published as New Cholesterol Guidelines Loom

AUM Cardiovascular Receives FDA Approval For Revolutionary Diagnostic Heart Device

ABSORB II Substudy Digs Into Long-term Arterial Remodeling Following BRS, DES Implantation

Less Than Half of ACS Patients Are Prescribed High-Potency Statin Therapy

Las Noticias y Blogs Más Populares de TCTMD en 2016

Los Antecedentes de Aterosclerosis Aumentan el Riesgo de Morir Post-IAM

USPSTF: Counseling on Diet and Exercise Helpful but Not Mandatory for CVD Prevention

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

Más con Menos: Un Análisis de Rentabilidad Dice que Hay que Reducir en Dos Tercios el Precio de PCSK9

Focus on LDL Cholesterol Targets With Statin Therapy, New ESC-EAS Cholesterol Guidelines Say

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content